Phio Pharmaceuticals (NASDAQ:PHIO) Trading Down 0.8%

Shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) were down 0.8% on Friday . The company traded as low as $2.50 and last traded at $2.61. Approximately 17,596 shares were traded during mid-day trading, a decline of 49% from the average daily volume of 34,431 shares. The stock had previously closed at $2.63.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of Phio Pharmaceuticals in a research report on Tuesday, May 14th.

Phio Pharmaceuticals Trading Down 0.8 %

The company has a 50-day moving average price of $3.68 and a 200-day moving average price of $5.83.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($3.62) earnings per share for the quarter, topping the consensus estimate of ($4.59) by $0.97. Equities research analysts predict that Phio Pharmaceuticals Corp. will post -16.38 earnings per share for the current fiscal year.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.